Table 4.
Main pathological characteristics of CD20-negative diffuse large B-cell lymphoma and CD20-positive diffuse large B-cell lymphoma patients
| Total (tested) | CD20-negative DLBCL(n = 28) | CD20-positive DLBCL(n = 84) | P | |
|---|---|---|---|---|
|
IHC Subtypes |
|
|
|
|
| GCB |
26(48.1%) |
5(22.7%) |
21(65.6%) |
0.002 |
| non-GCB |
28(51.9%) |
17(77.3%) |
11(34.4%) |
|
|
Ki-67 |
|
|
|
|
| ≥80% |
30(42.3%) |
17(70.8%) |
13(27.7%) |
<0.001 |
| <80% |
41(57.7%) |
7(29.2%) |
34(72.3%) |
|
|
BCL-2 |
|
|
|
|
| Positive |
37(54.4%) |
13(65%) |
24(50%) |
0.258 |
| Negative |
31(45.6%) |
7(35%) |
24(50%) |
|
|
EBERs |
|
|
|
|
| Positive |
2(6.9%) |
1(4.8%) |
1(12.5%) |
0.483 |
| Negative |
27(93.1%) |
20(95.2%) |
7(87.5%) |
|
|
CD30 |
|
|
|
|
| Positive |
14(19.4%) |
9(36%) |
5(10.6%) |
0.023 |
| Negative |
58(80.6%) |
16(64%) |
42(89.4%) |
|
|
ALK |
|
|
|
|
| Positive |
7(20.6%) |
5(20.8%) |
2(20%) |
1 |
| Negative |
27(79.4%) |
19(79.2%) |
8(80%) |
|
|
Specified DLBCL |
|
|
|
|
| ALK-positive LBCL |
5(4.5%) |
5(17.9%) |
0(0) |
0.001 |
| PBL |
2(1.8%) |
2(7.1%) |
0(0) |
0.061 |
| PEL |
0(0) |
0(0) |
0(0) |
1 |
| DLBCL with PD | 4(3.6%) | 3(10.7%) | 1(1.2%) | 0.078 |
IHC, Immunohistochemical; GCB, germinal centre B-cell; DLBCL, diffuse large B-cell lymphoma; LBCL, large B-cell lymphoma; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; PD, plasmacytic differentiation.